A Phase 2 interventional study of GnRH iontophoretic transdermal Lutrepatch and GnRH iontophoretic transdermal Lutrepatch in Infertility, sponsored by Ferring Pharmaceuticals. Completed at 35 sites in United States. Open to female participants aged 18 Years to 38 Years. Per ClinicalTrials.gov, last updated 2015-09-09.
Sponsored by Ferring Pharmaceuticals · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 39 studies in Infertility by Ferring Pharmaceuticals — none open to participants now, 2 under way, none of them phase 3. Infertility · Ferring Pharmaceuticals.
Among the 39 studies in Infertility by Ferring Pharmaceuticals, this one is the 9th largest by enrollment of the 27 interventional ones that give a count, is one of 3 that started in 2009, is one of 6 in phase 2, and was the 3rd registered.
2,089 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →None of the 39 studies in Infertility by Ferring Pharmaceuticals is open now. The open studies under Infertility, anywhere →
Of the 233 Infertility studies recruiting now, 43 (18%) set no upper age limit and 184 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 38 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
39 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 7 · Phase 3 12 · Phase 4 6
First in 2004; this study’s year is marked. 3 started in 2009.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 350 is above the median of 134 across 1,414 interventional studies indexed under Infertility.
Median enrollment 220 across the 27 interventional studies, 355 across the 12 observational. Of the 35 that completed or were terminated, 18 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
Ferring Pharmaceuticals is the lead sponsor of 249 studies on the registry; 4 are open to participants now.
Of its 15 completed or terminated interventional studies of FDA-regulated products, 14 (93%) have results posted.
1 of the studies in Infertility by Ferring Pharmaceuticals that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06561958Ferring PharmaceuticalsProspective, Multi-centre, Non-Interventional Study to Investigate the Effectiveness of REKOVELLE® for Ovarian Stimulation for Asian Women in Real World Settings | 2027-05-01 |
Add it to your calendar (.ics) → With an account.
Among the 39 studies in Infertility by Ferring Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary objective of this study is to determine the safety and efficacy of pulsatile GnRH delivered from a iontophoretic patch (Lutrepatch) for induction of ovulation in women with anovulatory/ oligoovulatory infertility, compared to placebo and to a reference treatment with clomiphene citrate.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Infertile due to ovulatory dysfunction as described below:
Exclusion Criteria:
10 mg GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
Drug: GnRH iontophoretic transdermal Lutrepatch · Drug: placebo clomiphene citrate
10 mg GnRH iontophoretic transdermal Lutrepatch with a medium target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
Drug: GnRH iontophoretic transdermal Lutrepatch · Drug: placebo clomiphene citrate
10 mg GnRH iontophoretic transdermal Lutrepatch with a low target delivery of pulsatile GnRH (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
Drug: GnRH iontophoretic transdermal Lutrepatch · Drug: placebo clomiphene citrate
Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral 50 mg clomiphene citrate for 5 days
Drug: clomiphene citrate · Drug: placebo GnRH patch
Placebo GnRH iontophoretic transdermal Lutrepatch with a high target delivery of pulsatile current (every 90 minutes) for 21 days and oral placebo clomiphene citrate for 5 days
Drug: placebo clomiphene citrate · Drug: placebo GnRH patch
10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml
Also known as: Lutrepatch, Gonadotropin-releasing hormone (GnRH)
10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml
Also known as: Gonadotropin-releasing hormone (GnRH), Lutrepatch
10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml
Also known as: Gonadotropin-releasing hormone (GnRH), Lutrepatch
Oral, 50 mg daily for 5 days
Also known as: various tradenames
oral, taken for 5 days
Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
Ovulation rate
Time frame: 30 days
Pregnancy rate
Time frame: 30 days
Incidence of Ovarian Hyperstimulation Syndrome (OHSS)
Time frame: 30 days
Incidence of skin irritation
Time frame: 30 days
The record gives a start of Feb 2009, a primary completion of Dec 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gonadotropin-Releasing Hormone